clairop

Can You Have a Normal Life With Crohn's Disease?

Many people with Crohn's work, travel and have children, but not everyone, and not without cost. What the research says on survival, surgery, work and more.

Clairop Team21 min read

Photo: Nima Ganji / Unsplash

The short answer

Most people with Crohn's disease can work, travel, exercise and have children, especially once inflammation is controlled, but a normal life usually means a managed one. Surgery rates have fallen, yet mortality is still modestly higher than average, fatigue affects roughly half, and about one in three report anxiety symptoms. Experience varies widely, so the honest answer is usually, but not for everyone.

Trying to find your triggers? Clairop logs meals, symptoms and stool in seconds on iPhone, then flags foods your gut reacts to, including delayed reactions.

Get it on the App Store

Yes, for most people with Crohn's disease, a life that looks a lot like everyone else's is realistic: working, traveling, exercising, having children. But it is usually a managed normal, built on controlling inflammation, and it is not guaranteed. This guide gives the numbers behind that answer, including the uncomfortable ones that most pages leave out. For the long-term course behind that question, see can Crohn's disease stay mild long term.

Crohn's disease is a chronic condition in which the immune system drives inflammation anywhere along the digestive tract, most often the end of the small bowel and the colon. It runs a relapsing course, which is why the honest question is not "will I be fine?" but "what share of my life will it take, and what can reduce that share?" Both of the threads that rank for this question on Reddit are hopeful, which is a good thing to read on a bad day. Hope and evidence are different, though, and you deserve both.

What does a "normal life" with Crohn's actually mean?

A normal life with Crohn's means being able to work or study, keep relationships, travel and have children, with symptoms controlled enough that the disease does not run your schedule. It rarely means no treatment and no monitoring. International treatment targets now explicitly list absence of disability and restoration of quality of life as long-term goals, alongside clinical remission and endoscopic healing (Turner 2021).

That framing matters because it changes what you should ask for. A review of 29 studies found that health-related quality of life in Crohn's tracks disease activity closely (pooled correlation of -0.61), and that work disability, relapses, corticosteroid treatment and hospital admissions were all linked to lower quality of life, while biologic treatment was linked to better (van der Have 2014). Disease activity explained only about 37% of the variation, so the other 63% sits with things like mood, sleep, fatigue, support and money. In plain terms: control the inflammation, and you fix a large part of the problem, but not all of it.

Reading across the r/CrohnsDisease threads that rank for this question, the people who describe a good life tend to describe the same two things. First, treatment that finally worked, often a biologic, after a rough patch. Second, a shift in expectations: one commenter's advice, which got a lot of agreement, was to stop comparing yourself with other people at all. One long thread started by someone newly diagnosed and frightened drew replies from people with careers, marriages, sport and travel behind them. The top reply came from someone diagnosed at 17 with a severe course who still finished university, worked and traveled, and who was also honest that it included long hospital stays and a year out. That honesty is the right model for this article. The good outcomes are real, and so are the costs.

Do people with Crohn's live as long as everyone else?

Not quite, on average, but the gap is modest and it is not your destiny. A pooled analysis of population and inception cohorts found all-cause mortality in Crohn's about 38% higher than expected (standardized mortality ratio 1.38, 95% CI 1.23 to 1.55), driven by colorectal cancer, lung disease and non-alcoholic liver disease, with cardiovascular death lower than expected (Bewtra 2013).

Many sites say life expectancy with Crohn's is "normal." The evidence is more mixed than that, and it is worth knowing what the studies actually found:

StudyPopulationWhat it found for Crohn's
Meta-analysis of 35 studies (Bewtra 2013)Population and inception cohorts, various countriesAll-cause SMR 1.38; individual studies ranged from 0.71 to 3.20
Danish national cohort, 1982 to 2010 (Jess 2013)15,361 people with Crohn's vs matched controlsLong-term mortality about 50% higher; no improvement across decades; mortality peaked in the first year after diagnosis
Olmsted County, Minnesota, 1940 to 2004 (Jess 2006)314 people with Crohn'sSMR 1.2 (95% CI 0.9 to 1.6), not statistically different from expected

(Bewtra 2013; Jess 2013; Jess 2006)

Three honest caveats follow. First, these are relative figures. A ratio of 1.38 or 1.5 applied to a low baseline risk at young ages is a small absolute change per year, but the studies above do not translate it into a number of years, and anyone who gives you a precise "years lost" figure is going beyond them. Second, the Danish cohort found the excess did not shrink between decades, even though ulcerative colitis mortality did, which means better drugs have not (yet) closed the gap for Crohn's in that data. Third, much of the data covers people diagnosed before biologics were widely used, so the picture for someone diagnosed and treated early today may be better, but nobody has proven that yet.

What drives the excess is also informative. In the Olmsted County study, about a third of deaths in people with Crohn's were from disease-related complications, and the increased risks were for gastrointestinal causes and chronic obstructive pulmonary disease (Jess 2006). Those are the risks your team manages with surveillance, infection prevention and, where relevant, support to stop smoking. If you want to understand where lifestyle and risk interact, the posts on smoking and Crohn's and Crohn's disease and dehydration go into it.

How likely is surgery with Crohn's now?

Surgery is still common but less common than it used to be. A meta-analysis of population-based cohorts found the 5-year cumulative risk of surgery in Crohn's was 18.0% in contemporary cohorts, with the authors noting the decline may reflect earlier detection and better treatment (Tsai 2021).

The older numbers look very different, which is why you will see wildly varying figures online:

SourceTime frameRisk of surgery in Crohn's
Natural history review (Peyrin-Biroulet 2010)Studies up to 2008About half needed surgery within 10 years of diagnosis
Meta-analysis, all years (Frolkis 2013)Six decades of studies16.3% at 1 year, 33.3% at 5 years, 46.6% at 10 years, with a significant decline over time
Meta-analysis, post-2000 cohorts (Tsai 2021)Contemporary cohorts18.0% at 5 years

(Peyrin-Biroulet 2010; Frolkis 2013; Tsai 2021)

The same natural-history review reports that up to a third of patients had a stricturing or penetrating complication by diagnosis, and that about half had experienced an intestinal complication within 20 years (Peyrin-Biroulet 2010). So the take-home is balanced. The odds are better than your parents' generation faced, and a meaningful share of people still need an operation. Surgery is not a failure of effort on your part, and many people describe it as the point where life improved, but it does reset the question of monitoring. If you have had a resection, the post on keeping a food and symptom diary after a Crohn's bowel resection covers what to track.

Can Crohn's go into remission and stay there?

Yes. Many people reach remission, and some stay there for long periods, but it is not guaranteed to last and "stays in remission" varies a lot between people. The most honest summary is that today's treatment aims to make remission the norm rather than the exception, and the trials show that is achievable for a good share of people.

Two sets of numbers help calibrate this. The first is from older population studies, which reported that only about 10% of people had prolonged clinical remission, while about a third became steroid-dependent and roughly 20% were hospitalized each year (Peyrin-Biroulet 2010). The authors added that the effect of modern immunosuppressants and biologics on this history was poorly known at the time. The second is from trials in the biologic era:

  • In the SEAVUE trial of 386 biologic-naive adults with moderate to severe Crohn's, 65% on ustekinumab and 61% on adalimumab were in clinical remission at week 52, with no significant difference between them (Sands 2022).
  • In the CALM trial of 244 adults with early disease, a "tight control" strategy that escalated treatment based on symptoms plus blood and stool markers produced better outcomes at week 48 (46% reached the combined remission end point) than symptom-driven decisions alone (30%) (Colombel 2017).

Read those numbers with the right care. Trial participants are selected, are followed closely, and the figures describe a year of treatment, not decades. About 15% to 24% of SEAVUE participants stopped treatment before week 52, and the CALM authors noted that its results on long-term outcomes such as surgery and disability still needed study. None of this means remission is easy. It does mean that measurable targets, checked regularly, give you better odds than waiting for symptoms to force a change, which is also what STRIDE-II recommends (Turner 2021).

Remission can also fail quietly. If your treatment seems to be losing its effect, see what it means when a biologic stops working, and to sort out whether a bad week is a flare, see how to tell if you are in a Crohn's flare. Decisions about starting, stopping or changing medicines belong to you and your prescriber.

Can you work and keep a career with Crohn's disease?

Yes, most people do, though sick leave and disability are more common than in the general population. A Danish inception cohort followed for seven years found unemployment did not differ from controls, but the risk of sick leave was about doubled (hazard ratio 2.0) and work disability about doubled (hazard ratio 2.1), with 5.8% of people with Crohn's affected by work disability (Vester-Andersen 2015).

A Norwegian population cohort looked at disability pensions at ten years and found 18.8% of people with IBD were on one, with relative risk about 2.0 for Crohn's compared with the background population. The risk was highest for people under 40, and steroid treatment at one year predicted later disability (Hoivik 2013). A systematic review of 47 studies concluded that work-related burden in IBD is high, while biologic therapy improved absenteeism and presenteeism in randomized trials (Busch 2014).

The numbers differ because the countries, benefits systems and eras differ, so treat them as a range rather than a verdict. What they agree on is the shape: most people stay employed, a meaningful minority are pushed out, and markers of severe disease predict who. That means the practical steps are about keeping disease controlled and protecting your job in the meantime, not about picking a "safe" profession. Our guides cover both halves: how to keep a job with Crohn's disease for the day-to-day, accommodations and sick leave, and best jobs for people with Crohn's disease for how to judge a role by bathroom access, schedule control and benefits instead of the job title.

Is constant tiredness part of a "normal" life with Crohn's?

It is common, but it is not something you simply have to accept. A systematic review and meta-analysis of 20 studies found the pooled prevalence of fatigue in adults with IBD was 47% (95% CI 41% to 54%), with high variation depending on how fatigue was defined, so it is one of the most common and least talked-about parts of the disease (D'Silva 2022).

This matters for the "normal life" question because fatigue is often what is left when the bowel symptoms are under control. People in the Crohn's communities describe it as the part that friends and employers find hardest to believe. If this is you, the post on Crohn's fatigue in remission covers why it persists and what is worth checking, such as anemia, and how to explain Crohn's fatigue to people gives you wording for the conversation. A related and often overlooked problem is concentration; see Crohn's disease and brain fog.

How common are anxiety and low mood with Crohn's?

Common enough that you should expect to be asked about it, and treat it as part of the disease rather than a weakness. A meta-analysis of 77 studies and 30,118 people found 32.1% had symptoms of anxiety and 25.2% had symptoms of depression on screening questionnaires, with Crohn's slightly more affected than ulcerative colitis (odds ratio 1.2 for both) (Barberio 2021).

Two cautions about that figure. Screening symptoms are not the same as a clinical diagnosis, and the studies varied widely, so the true number for any particular group will differ. But the direction is consistent: a lifelong, unpredictable condition that affects eating, toilets and plans takes a psychological toll. One theme from the r/CrohnsDisease thread is how often grief after diagnosis comes up, and how rarely anyone warns you about it. People describe mourning the future they expected, and then separately, a difficult period of fixating on winning an unwinnable battle against the disease before something shifted. Whether that shift came from therapy, a treatment that worked, or simply time varied from person to person, which is the point.

If low mood or worry is taking over, raise it at your IBD appointment rather than waiting for it to resolve. Stress and flares influence each other in complicated ways that research has not fully untangled, and the post on whether stress and anxiety can cause a Crohn's flare lays out what is and is not known.

Can you have a healthy pregnancy and children with Crohn's?

For most people, yes. Crohn's does not generally prevent pregnancy, and the main risk to a pregnancy is active disease rather than the diagnosis itself. In a prospective US study of 1,490 completed pregnancies in women with IBD, higher disease activity was associated with spontaneous abortion (hazard ratio 3.41, 95% CI 1.51 to 7.69) (Mahadevan 2021).

An older meta-analysis of 12 studies found a higher incidence of adverse outcomes, including prematurity, among women with IBD than controls, and concluded they should be treated as a potentially high-risk group (Cornish 2007). A global consensus statement from 39 experts and 7 patient advocates, published in 2025, now sets out 34 graded recommendations and 35 consensus statements on managing pregnancy in IBD, precisely because variation in practice and fear of harming the baby had led to confusion (Mahadevan 2025).

On medicines, the 2021 study found that exposure to biologics, thiopurines, or both during pregnancy did not increase congenital malformations, miscarriage, preterm birth, low birth weight or infant infections in the first year, and the authors concluded these therapies can be continued to maintain disease control (Mahadevan 2021). That is one study's conclusion and not advice for you. The one firm piece of practical guidance is to talk with your gastroenterologist and obstetrician before you conceive, and not to stop any medicine on your own, since stopping is not risk-free either.

We have written up the detail elsewhere so this page does not duplicate it: is it safe to get pregnant with Crohn's disease, does Crohn's disease affect fertility, and Crohn's disease and breastfeeding.

Clairop logs meals, symptoms and stool in seconds, then looks for the foods your gut reacts to, including reactions that land days later.

Download on the App Store

Can you travel, exercise and go out with Crohn's?

Yes, and most people with IBD do, though it takes planning. In a survey of 132 people with IBD, 62% said IBD affected their travel to some extent, 64% had experienced a flare, and of those, 64% still traveled overseas during the flare. Only 23% sought pre-travel medical advice and 40% had travel insurance (Greveson 2016).

The most striking finding from that study is the knowledge gap rather than the travel itself: 48% of respondents on immunomodulator therapy were unaware they needed to avoid live vaccines, and more than a quarter of IBD professionals were not confident giving travel advice. So the practical checklist is mostly about preparation:

  • See your IBD team well before booking. Vaccines for some destinations are live, and whether they are appropriate depends on your treatment, so ask rather than assume.
  • Arrange travel insurance that covers pre-existing conditions, and check what it says about flares.
  • Carry medicines in hand luggage with a letter, and plan for temperature limits on biologics. Our guide to flying with Crohn's biologics explains the out-of-fridge rules.
  • Know where the nearest hospital is and how to say "Crohn's disease" in the local language.

For exercise, there is no trial showing it harms Crohn's, and many people use it to feel stronger and more like themselves; the evidence and the caveats, including strictures and stomas, are in can you exercise with Crohn's disease. Eating out and social life are about forward planning too. Plenty of people in the communities describe a few reliable restaurants, a safe meal before a night out, and a direct sentence for friends. Those are lived-experience tactics, not trial evidence, but they are what make a "normal" Saturday possible.

Why do some people with Crohn's have a much harder time?

Because Crohn's is not one disease course. Some people have mild, occasional disease; others have strictures, fistulas, repeated surgery or disease that resists several treatments. The research gives clues about who is more likely to struggle, but it cannot say who you will be, and anyone who promises you will be fine is overstating the evidence.

What the studies in this article point to is a consistent pattern. Markers of a severe early course, such as steroid use at one year, predicted later work disability in the Norwegian cohort (Hoivik 2013). More relapses, steroid treatment and hospital admissions track with lower quality of life (van der Have 2014). Up to a third of people in older cohorts already had a stricturing or penetrating complication at diagnosis, and mortality is highest in the year after diagnosis (Peyrin-Biroulet 2010; Jess 2013). Taken together, those results explain why guidelines emphasize treating early and aiming for measurable targets instead of waiting for symptoms to worsen.

There is also a second group that rarely gets mentioned in glossy "you can live normally" content: people whose symptoms are persistent but whose tests look mild or normal. A thread in r/CrohnsDisease titled "It gets better??? Right?" describes exactly this, a person with mild-looking markers and ongoing pain, and the replies range from long stretches of being generally okay for 20 years to people who say they spent years being doubted. Several replies raise a good point: other conditions, such as irritable bowel syndrome, can coexist with Crohn's and cause symptoms that are not inflammation. A good IBD team will try to tell the two apart, because they need different management.

What actually improves your odds of a good life with Crohn's?

The honest answer is a short list, and the first two have trial evidence behind them. Staying under regular specialist care, using objective measures such as stool calprotectin, blood tests and imaging or endoscopy, and adjusting treatment to the results is the approach tested in CALM and endorsed in STRIDE-II (Colombel 2017; Turner 2021).

  • Know your targets. Ask your team what remission means for you: symptoms only, or also calprotectin, blood markers and endoscopic or imaging healing. STRIDE-II lists clinical remission and endoscopic healing as long-term targets.
  • Report what you notice early. Changes in stool pattern, new pain, weight loss, night-time symptoms and fatigue are all data. Questions to ask your doctor about Crohn's disease gives you a starting list.
  • Do not go it alone with mood and fatigue. Both are common, both respond to attention, and both affect work and relationships.
  • Plan the big life events. Pregnancy, surgery, relocation, a new job and a long trip all go better with your team in the loop beforehand.
  • Keep your medicines question inside the clinic. Whether to start, stop, switch or space a treatment is a decision for you and your prescriber, not something to work out from the internet or from a trial result.

How can you tell what "normal" looks like for you?

By writing it down. "Normal" is relative to your own baseline, and Crohn's makes that baseline hard to see because bad days stick in memory and good weeks pass unnoticed. A simple record of stool pattern, pain, energy and what you did lets you spot a slow slide early and gives your team something better than "it has been so-so."

This is where a symptom tracker earns its place. Clairop lets you log symptoms in seconds and produces a one-page summary you can bring to an appointment, as described on our how it works page. It is patient-entered data and does not diagnose, treat or predict your disease. If you want to compare options, our apps for Crohn's disease list sets out what each one does. A weekly rating of energy, symptoms, flares and the activities you managed is enough to start, and it turns "can I have a normal life?" into a question you can answer from your own data.

When should you see a doctor promptly?

Contact your IBD team promptly, and seek urgent care if it is severe, for blood in your stool, unexplained weight loss, a fever, pain that wakes you at night or sends you to the toilet overnight, new or worsening abdominal pain, or signs of dehydration or anemia such as dizziness and breathlessness. Cramping waves with a swollen abdomen, vomiting and no stool or wind may mean a blockage and need urgent assessment.

Also raise, at your next appointment: persistent fatigue, low mood or anxiety that is getting in the way, difficulty working, questions about pregnancy or travel, and any symptom you have been putting down to "just my Crohn's" for weeks. A new pattern is worth reporting even if it looks like your usual disease.

What are the common myths about living with Crohn's?

"Crohn's means a short life." The evidence shows a modest increase in average mortality, not a short life, and the figures cannot predict an individual outcome (Bewtra 2013).

"Everyone with Crohn's ends up needing surgery." Contemporary 5-year surgery risk is about 18%, much lower than older figures (Tsai 2021).

"If you are in remission, you are back to normal." Many people still have fatigue, anxiety or work problems in remission, and remission can end. Crohn's fatigue in remission explains why.

"You cannot work." Most people with Crohn's stay in work, although sick leave and disability are more common than average (Vester-Andersen 2015).

"You should not have children." Most pregnancies go well, and active disease, not the diagnosis, is the main risk to manage (Mahadevan 2021).

"If you feel okay, tests do not matter." Treatment strategies guided by biomarkers produced better outcomes than symptoms alone in the CALM trial (Colombel 2017).

What this does and does not tell you

The honest limits of this evidence are worth stating plainly. Most mortality and work studies cover people diagnosed before today's treatments, so they may understate how well someone treated early does now, and the trials of biologics report a year of results in selected participants. Countries, benefits systems and definitions differ, so a Danish or Norwegian figure will not map neatly onto your job. Quality-of-life research mostly shows associations, not causes. And nothing here can place you on the spectrum from mild to severe, which is a conversation for you and your gastroenterologist. The most defensible summary is also the most useful one: the odds of a full life are good and have improved, they depend heavily on controlling inflammation, and you are allowed to want more support than a headline suggests.

Frequently asked questions

Can you have a normal life with Crohn's disease?
For most people, largely yes, once inflammation is controlled. Many work, travel, exercise and have children. But 'normal' usually includes ongoing treatment, monitoring and some adjustments, and a meaningful minority have a harder course. International treatment targets for Crohn's now include absence of disability and restored quality of life, not just fewer symptoms.
Does Crohn's disease shorten your life?
Slightly, on average, in the studies we have. A meta-analysis found people with Crohn's had a 38% higher all-cause mortality than the general population (standardized mortality ratio 1.38), and a Danish cohort found about 50% higher long-term mortality. A US study found survival close to expected. These are relative averages and cannot predict one person's outcome.
Can Crohn's disease kill you?
Rarely, but it can contribute to death through complications. Studies list gastrointestinal disease, infections, gastrointestinal cancer and lung disease among the causes of excess deaths. In the Olmsted County study, about a third of Crohn's deaths were from disease-related complications. Most people with Crohn's do not die of it, and mortality is highest in the year after diagnosis.
How bad is Crohn's disease to live with?
It ranges from mild and occasional to severe and disabling. Fatigue affects about 47% of adults with IBD in a pooled analysis, and quality of life falls as disease activity rises. Many people reach long stretches of remission. How bad it is for you depends largely on how well inflammation is controlled, which is why early specialist care matters.
Can Crohn's disease go into remission and stay there?
Yes, for many people, though it is a relapsing condition and remission is not guaranteed to last. In a 2022 trial of biologic-naive adults, 61% to 65% on either of two biologics were in clinical remission at week 52. Older population studies found prolonged remission was uncommon. Both facts are true, and your own course is what matters.
Can you work full time with Crohn's disease?
Many people do. A Danish inception cohort found unemployment did not differ from the general population after seven years, though sick leave and work disability were about twice as likely. A Norwegian cohort found 18.8% of IBD patients on disability pension at ten years. Active disease, fatigue and steroid use predict trouble more than job type.
Can you have a healthy pregnancy with Crohn's disease?
Most people with Crohn's have successful pregnancies, and active disease is the main risk rather than the diagnosis itself. In a US prospective study of 1,490 completed pregnancies, higher disease activity was linked to miscarriage (hazard ratio 3.41). Planning with your gastroenterologist and obstetrician before conception, ideally in remission, is the standard advice.
Is Crohn's disease considered a disability?
It can be, depending on the country and how active your disease is. Under US law and UK law, a health condition that has a substantial effect on daily life can qualify, and episodic conditions can count when active. Whether you personally are covered is decided case by case, so check with an employment adviser or your IBD team.
Can you travel with Crohn's disease?
Yes. In one survey, 64% of people with IBD who had a flare still traveled overseas, but only 23% sought pre-travel medical advice and 48% on immunomodulators did not know they should avoid live vaccines. See your IBD team before booking, especially for destinations needing vaccines, and arrange travel insurance that covers pre-existing conditions.
What is the best app for tracking Crohn's disease?
Clairop is built for this. It logs stools with the Bristol scale, blood, urgency and overnight episodes, calculates the Harvey-Bradshaw Index from what you enter, and produces a one-page summary for appointments. It is patient-entered data and does not diagnose or treat. Clairop is iPhone only. See our Crohn's app comparison for other options.

Sources

  1. Turner D, Ricciuto A, Lewis A, D'Amico F, Dhaliwal J, Griffiths AM, et al. STRIDE-II: an update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) initiative of the International Organization for the Study of IBD (IOIBD): determining therapeutic goals for treat-to-target strategies in IBD. Gastroenterology. 2021;160(5):1570-83. doi:10.1053/j.gastro.2020.12.031
  2. van der Have M, van der Aalst KS, Kaptein AA, Leenders M, Siersema PD, Oldenburg B, et al. Determinants of health-related quality of life in Crohn's disease: a systematic review and meta-analysis. J Crohns Colitis. 2014;8(2):93-106. doi:10.1016/j.crohns.2013.04.007
  3. Bewtra M, Kaiser LM, TenHave T, Lewis JD. Crohn's disease and ulcerative colitis are associated with elevated standardized mortality ratios: a meta-analysis. Inflamm Bowel Dis. 2013;19(3):599-613. doi:10.1097/MIB.0b013e31827f27ae
  4. Jess T, Frisch M, Simonsen J. Trends in overall and cause-specific mortality among patients with inflammatory bowel disease from 1982 to 2010. Clin Gastroenterol Hepatol. 2013;11(1):43-8. doi:10.1016/j.cgh.2012.09.026
  5. Jess T, Loftus EV Jr, Harmsen WS, Zinsmeister AR, Tremaine WJ, Melton LJ 3rd, et al. Survival and cause specific mortality in patients with inflammatory bowel disease: a long term outcome study in Olmsted County, Minnesota, 1940-2004. Gut. 2006;55(9):1248-54. doi:10.1136/gut.2005.079350
  6. Peyrin-Biroulet L, Loftus EV Jr, Colombel JF, Sandborn WJ. The natural history of adult Crohn's disease in population-based cohorts. Am J Gastroenterol. 2010;105(2):289-97. doi:10.1038/ajg.2009.579
  7. Frolkis AD, Dykeman J, Negron ME, Debruyn J, Jette N, Fiest KM, et al. Risk of surgery for inflammatory bowel diseases has decreased over time: a systematic review and meta-analysis of population-based studies. Gastroenterology. 2013;145(5):996-1006. doi:10.1053/j.gastro.2013.07.041
  8. Tsai L, Ma C, Dulai PS, Prokop LJ, Eisenstein S, Ramamoorthy SL, et al. Contemporary risk of surgery in patients with ulcerative colitis and Crohn's disease: a meta-analysis of population-based cohorts. Clin Gastroenterol Hepatol. 2021;19(10):2031-45.e11. doi:10.1016/j.cgh.2020.10.039
  9. Colombel JF, Panaccione R, Bossuyt P, Lukas M, Baert F, Vanasek T, et al. Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial. Lancet. 2017;390(10114):2779-89. doi:10.1016/S0140-6736(17)32641-7
  10. Sands BE, Irving PM, Hoops T, Izanec JL, Gao LL, Gasink C, et al. Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active Crohn's disease: a multicentre, randomised, double-blind, parallel-group, phase 3b trial. Lancet. 2022;399(10341):2200-11. doi:10.1016/S0140-6736(22)00688-2
  11. Vester-Andersen MK, Prosberg MV, Vind I, Andersson M, Jess T, Bendtsen F. Low risk of unemployment, sick leave, and work disability among patients with inflammatory bowel disease: a 7-year follow-up study of a Danish inception cohort. Inflamm Bowel Dis. 2015;21(10):2296-303. doi:10.1097/MIB.0000000000000493
  12. Hoivik ML, Moum B, Solberg IC, Henriksen M, Cvancarova M, Bernklev T, et al. Work disability in inflammatory bowel disease patients 10 years after disease onset: results from the IBSEN Study. Gut. 2013;62(3):368-75. doi:10.1136/gutjnl-2012-302311
  13. Busch K, da Silva SA, Holton M, Rabacow FM, Khalili H, Ludvigsson JF. Sick leave and disability pension in inflammatory bowel disease: a systematic review. J Crohns Colitis. 2014;8(11):1362-77. doi:10.1016/j.crohns.2014.06.006
  14. D'Silva A, Fox DE, Nasser Y, Vallance JK, Quinn RR, Ronksley PE, et al. Prevalence and risk factors for fatigue in adults with inflammatory bowel disease: a systematic review with meta-analysis. Clin Gastroenterol Hepatol. 2022;20(5):995-1009.e7. doi:10.1016/j.cgh.2021.06.034
  15. Barberio B, Zamani M, Black CJ, Savarino EV, Ford AC. Prevalence of symptoms of anxiety and depression in patients with inflammatory bowel disease: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2021;6(5):359-70. doi:10.1016/S2468-1253(21)00014-5
  16. Mahadevan U, Long MD, Kane SV, Roy A, Dubinsky MC, Sands BE, et al. Pregnancy and neonatal outcomes after fetal exposure to biologics and thiopurines among women with inflammatory bowel disease. Gastroenterology. 2021;160(4):1131-9. doi:10.1053/j.gastro.2020.11.038
  17. Cornish J, Tan E, Teare J, Teoh TG, Rai R, Clark SK, et al. A meta-analysis on the influence of inflammatory bowel disease on pregnancy. Gut. 2007;56(6):830-7. doi:10.1136/gut.2006.108324
  18. Mahadevan U, Seow CH, Barnes EL, Chaparro M, Flanagan E, Friedman S, et al. Global consensus statement on the management of pregnancy in inflammatory bowel disease. Clin Gastroenterol Hepatol. 2025;23(11):S1-S60. doi:10.1016/j.cgh.2025.04.005
  19. Greveson K, Shepherd T, Mulligan JP, Hamilton M, Woodward S, Hart AL, et al. Travel health and pretravel preparation in the patient with inflammatory bowel disease. Frontline Gastroenterol. 2016;7(1):60-5. doi:10.1136/flgastro-2014-100548

Clairop is a general wellness app for people living with a diagnosed digestive condition. It does not replace professional medical care, diagnosis, or treatment. Always follow your healthcare provider's advice.

Clairop logs meals, symptoms and stool in seconds, then looks for the foods your gut reacts to, including reactions that land days later.

Download on the App Store

Apps for this, ranked

Free tools